{{medical}}
{{Infobox drug
| drug_name =米屈肼
| INN =
| type =<!-- empty -->
| IUPAC_name = 2-(2-Carboxylato-ethyl)-1,1,1-trimethylhydrazinium
| synonyms = Mildronate；THP，MET-8 Mildronāts，或 Quaterine
| image = Meldonium Structural Formula V1.svg
| alt = 
| caption =
<!-- Clinical data -->
| pronounce =
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment = 
| pregnancy_US = <!-- A/B/C/D/X/N -->
| pregnancy_category = 
| routes_of_administration = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status = <!-- Free text -->

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| metabolites =
| onset = 
| elimination_half-life = 
| duration_of_action =
| excretion = 


<!-- Identifiers -->
| CAS_number = 86426-17-7
| CAS_number_Ref = {{cascite|correct|CAS}}
| ATCvet = 
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix = 
| PubChem = 123868
| DrugBank =    
| StdInChI = 1S/C6H14N2O2/c1-8(2,3)7-5-4-6(9)10/h7H,4-5H2,1-3H3
| StdInChIKey = PVBQYTCFVWZSJK-UHFFFAOYSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 73H7UDN6EC
| ChemSpiderID = 110405
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| SMILES = C[N+](C)(C)NCCC(=O)[O-]

<!-- Chemical data -->
| chemical_formula = C<sub>6</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup>
| molecular_weight = 147.19 g/mol
| solubility= >40 mg/mL
<!-- data originally in {{Chembox}}, unfit for Drugbox (Mar 2016):
| Appearance= White to off-white powder 
| ExternalMSDS = [http://www.sigmaaldrich.com/catalog/product/sigma/m5199 MSDS] -->
}}

'''米屈肼'''（{{lang|en|'''Meldonium'''}}，亦有譯作'''米曲肼'''，商品名為'''Mildronate'''，又名'''MET-88'''、'''Mildronāts'''、'''Quaterine'''<ref>{{cite web |title=Patent Number: 1429753. |url=http://www.surechem.org/index.php?Action=document&docId=679316&db=EPB&tab=desc&lang=EN&db_query=2%3A0%3A&markupType=all |accessdate=2012-08-16 |language=en |deadurl=yes |archiveurl=https://web.archive.org/web/20131105230115/http://www.surechem.org/index.php?Action=document&docId=679316&db=EPB&tab=desc&lang=EN&db_query=2%3A0%3A&markupType=all |archivedate=2013-11-05 }}</ref>）或按其[[化學名稱|化學名稱]]縮寫作''THP''<ref name=PubChem />，一種受管制藥物，目前主要由位於[[拉脫維亞|拉脫維亞]]的{{tsl|en|Grindeks||Grindeks}}公司及另外數家替代藥物生產商所生產。現時這種藥物在[[東歐|東歐國家]]用作抗[[缺血|缺血]]藥物<ref>{{cite web |url=http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list |title=Grindeks: We Believe that Meldonium Should not be Included in the List of Banned Substances in Sport |publisher=Grindeks |date=2016-03-09 |accessdate=2016-03-09 |language=en |deadurl=yes |archiveurl=https://web.archive.org/web/20160312001639/http://www.grindeks.lv/en/for-media/latest-news/Grindeks-meldonium-should-not-be-included-in-the-prohibited-list |archivedate=2016-03-12 }}</ref>。

從2016年1月1日起，本藥被[[世界反運動禁藥機構|世界反運動禁藥機構]]（[[WADA|WADA]]）列為運動比賽的[[體育禁藥|禁藥]]<ref name="2016list">{{cite web |url=https://www.wada-ama.org/en/what-we-do/prohibited-list |title=Prohibited List |author= |date= |work=World Anti-Doping Agency |accessdate=2016-03-09 |language=en |archive-date=2017-07-12 |archive-url=https://web.archive.org/web/20170712212817/https://www.wada-ama.org/en/what-we-do/prohibited-list |dead-url=no }}</ref><ref>{{cite news |url=http://news.wenweipo.com/2016/03/08/IN1603080008.htm |title=莎拉波娃宣佈未通過興奮劑檢測 |publisher=[[文汇报_(香港)|文匯報]] |date=2016-03-08 |accessdate=2016-03-08 |language=zh |archive-date=2016-03-12 |archive-url=https://web.archive.org/web/20160312102313/http://news.wenweipo.com/2016/03/08/IN1603080008.htm |dead-url=no }}</ref>，因為米屈肼被認為是[[肉碱|左旋肉鹼]]的先導物質，具有提升服用者的體能耐久度的效果<ref>{{cite web|url=http://www.taiwanfansclub.com/article-360316-1.html|title=科普莎娃藥物：今年一月進入禁藥名單 能提升耐久性|accessdate=2016-03-08|date=2016-03-08|language=zh-hant|deadurl=yes|archiveurl=https://web.archive.org/web/20160308130041/http://www.taiwanfansclub.com/article-360316-1.html|archivedate=2016年3月8日|df=}}</ref>。然而，目前已知有運動員在此藥被列為禁藥之前就已在使用<ref>{{cite news |title=All About Meldonium, the Banned Drug Used by Sharapova |url=http://www.nytimes.com/2016/03/09/sports/tennis/what-is-meldonium-maria-sharapova.html?_r=0 |accessdate=2016-03-08 |agency=Associated Press |publisher=New York Times |date=2016-03-08 |language=en |archive-date=2020-05-23 |archive-url=https://web.archive.org/web/20200523135108/https://www.nytimes.com/2016/03/09/sports/tennis/what-is-meldonium-maria-sharapova.html?_r=0 |dead-url=no }}</ref>。

==醫療用途==
米屈肼在臨床上用於治療[[心绞痛|心絞痛]]（angina）和[[心肌梗塞|心肌梗塞]]（英語：myocardial infarction）<ref name="pmid16633095">{{cite journal | author = Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA | title = Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics | journal = Journal of Cardiovascular Pharmacology | volume = 47 | issue = 3 | pages = 493–9 |date=March 2006 | pmid = 16633095 | doi = 10.1097/01.fjc.0000211732.76668.d2 }}</ref><ref name="pmid17204911">{{cite journal | author = Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M | title = Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction | journal = Journal of Cardiovascular Pharmacology | volume = 48 | issue = 6 | pages = 314–9 |date=December 2006 | pmid = 17204911 | doi = 10.1097/01.fjc.0000250077.07702.23 }}</ref><ref name="pmid10812052">{{cite journal | author = Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N | title = Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction | journal = European Journal of Pharmacology | volume = 395 | issue = 3 | pages = 217–24 |date=May 2000 | pmid = 10812052 | doi = 10.1016/S0014-2999(00)00098-4 }}</ref>等[[冠狀動脈疾病|冠狀動脈疾病]](英語：Coronary artery disease, CAD)。
米屈肼的[[功效|功效]]的首次[[臨床試驗|臨床試驗]]在2005年進行，當時米屈肼與[[賴諾普利|賴諾普利]]（lisinopril，一種[[血管紧张肽I转化酶抑制剂|血管僅肽I轉化酶抑制劑]]）一起使用，以治療[[慢性心臟衰竭|慢性心臟衰竭]]。這次測試的結論是米屈肼與賴諾普利一併使用可改善[[生活質素|生活質素]]、運動耐力<ref>{{cite web|url=http://wwwc.moex.gov.tw/main/content/wHandMenuFile.ashx?menu_id%3D358%26blnMulFiles%3DFalse|author=[[方進隆|方進隆]]|title=心肺耐力和有氧運動訓練|pages=7|language=zh-hant|deadurl=yes|archiveurl=https://web.archive.org/web/20130129042545/http://wwwc.moex.gov.tw/main/content/wHandMenuFile.ashx?menu_id=358&blnMulFiles=False|archivedate=2013-01-29}}</ref>，及慢性[[心臟衰竭|心臟衰竭]]患者的[[循环系统|末梢循環]]機制。<ref name="trial2005">{{cite journal | author = Dzerve V, Matisone D, Kukulis I, Romanova J, Putane L, Grabauskiene˙V, Skarda I, Berzina D, Strautmanis J | title = Mildronate improves peripheral circulation in patients with chronic heart failure: results of a clinical trial (the ﬁrst report) | journal = Seminars in Cardiology | volume = 11 | issue = 2 | pages = 56–64 | year = 2005 | month =  | pmid =  | pmc =  | ISSN = 1648-7966 | url = http://www.seminarsincardiology.com/pdf/Seminars-2005-11-2-56-64.pdf | doi =  | deadurl = yes | archiveurl = https://web.archive.org/web/20120328094306/http://www.seminarsincardiology.com/pdf/Seminars-2005-11-2-56-64.pdf | archivedate = 2012-03-28 }}</ref>2008年的進一步研究報告認為，米曲肼和賴諾普利的併用可以改善慢性心臟衰竭患者的[[壓力感受器|頸動脈壓力感受器反射]](Baroreceptor)機制。<ref name="trial2008">{{cite journal | author = Vitols A, Voita D, Dzerve V | title = Mildronate improves carotid baroreceptor reﬂex function in patients with chronic heart failure | journal = Seminars in Cardiovascular Medicine | volume = 13 | issue =  | pages = 6 | year = 2008 | month =  | pmid =  | pmc =  | ISSN =  | url = http://www.seminarsincardiology.com/pdf/SeminarsCVMed-2007-13-6.pdf | doi =  | deadurl = yes | archiveurl = https://web.archive.org/web/20130921060004/http://www.seminarsincardiology.com/pdf/SeminarsCVMed-2007-13-6.pdf | archivedate = 2013-09-21 }}</ref>2010年2月，一次進一步的臨床試驗、測試心絞痛患者對於米曲肼與[[運動耐受力|標準運動耐受療法]](Exercise intolerance)的併合療法下之[[效能|效能]]及[[藥物警戒性|安全性]](Pharmacovigilance)，結果認為候選藥物可以顯著地改善[[心绞痛|穩定型心绞痛]]患者的[[運動耐受力|運動耐受力]](Exercise intolerance)。<ref name="trial1b">{{cite journal| author =Dzerve V, Matisone D, Pozdnyakov Y, Oganov R| title =Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial| journal =Seminars in Cardiovascular Medicine| volume =16| issue =| pages =3| year =2010| month =| pmid =| pmc =| ISSN =| url =http://www.seminarsincardiology.com/pdf/SeminarsCVMed-2010-16-3.pdf| doi =| deadurl =yes| archiveurl =https://web.archive.org/web/20130921060011/http://www.seminarsincardiology.com/pdf/SeminarsCVMed-2010-16-3.pdf| archivedate =2013-09-21}}</ref><ref name="trial1a">{{cite web|url=http://www.grindeks.lv/en/for-investors/stock-news/mildronate_clinical_trial|title=Stock news  / For investors / Leading pharmaceutical company in the Baltic - «Grindeks» JSC|author=|date=|work=grindeks.lv|accessdate=9 March 2016|deadurl=yes|archiveurl=https://web.archive.org/web/20160308052947/http://www.grindeks.lv/en/for-investors/stock-news/mildronate_clinical_trial|archivedate=2016年3月8日}}</ref><ref name="pmid22186118">{{cite journal |author=Dzerve V, MILSS I Study Group |title=A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial "MILSS I" |journal=Medicina (Kaunas) |volume=47 |issue=10 |pages=544–51 |year=2011 |month= |pmid=22186118 |pmc= |ISSN= |url=http://medicina.kmu.lt/1110/1110-04e.pdf |doi= |deadurl=yes |archiveurl=https://web.archive.org/web/20130921055503/http://medicina.kmu.lt/1110/1110-04e.pdf |archivedate=2013年9月21日 }}</ref> 

[[中國|中國]][[陝西|陝西]][[西安|西安]][[第四軍醫大學|第四軍醫大學]]的研究小組於2013年8月完成II期的臨床試驗，有227位患者參與。這次試驗是有關於米屈肼對於[[中風#缺血性中风|急性缺血性中風]]的療效、及[[藥物警戒性|藥物警戒性]](Pharmacovigilance)方面的運作機能。得出的結論認為米屈肼作為{{link-en|桂哌齊特|Cinepazide}}(Cinepazide)的注射劑是有效的及安全的。<ref name="trial2a">{{cite journal | author = Zhu Y, Zhang G, Zhao J, Li D, Yan X, Liu J, Liu X, Zhao H, Xia J, Zhang X, Li Z, Zhang B, Guo Z, Feng L, Zhang Z, Qu F, Zhao, G | title = Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial | journal = Clinical Drug Investigation | volume =  | issue =  | pages =  | year = 2013 | month =  | pmid =  | pmc =  | doi = 10.1007/s40261-013-0121-x }}</ref><ref name="trial2b">{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT01831011?rcv_d=14&lup_s=03%2F16%2F2013&lup_d=30|title=Mildronate for Acute Ischemic Stroke|author=|date=|work=clinicaltrials.gov|accessdate=9 March 2016|archive-date=2018-02-25|archive-url=https://web.archive.org/web/20180225064829/https://clinicaltrials.gov/ct2/show/NCT01831011?rcv_d=14&lup_s=03%2F16%2F2013&lup_d=30|dead-url=no}}</ref>

===使用許可===
截至2016年3月，儘管本藥已在東歐廣泛使用，但在美國尚未被[[美国食品药品监督管理局|美國食品药藥品監督管理局]](FDA)許可<ref>{{cite journal |url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1788/full |doi=10.1002/dta.1788 |authors=Görgens Christian, Guddat Sven, Dib Josef, Geyer Hans, Schänzer Wilhelm, Thevis Mario |title=Mildronate (Meldonium) in professional sports – monitoring doping control urine samples using hydrophilic interaction liquid chromatography – high resolution/high accuracy mass spectrometry. |journal=Drug Testing and Analysis |volume=7 |pages=973–979 |date=November–December 2015 |access-date=2016-03-08 |archive-date=2018-02-26 |archive-url=https://web.archive.org/web/20180226164722/http://onlinelibrary.wiley.com/doi/10.1002/dta.1788/full |dead-url=no }}</ref>。

===上市劑型===
[[File:Packaging_of_Mildronate.jpg|thumb]]

米屈肼的服用劑型、以250毫克及500毫克的膠囊劑包裝；注射劑型、則為含有10％劑量溶液的注射劑<ref>{{cite web|url=http://www.grindeks.lv/en/products/prescription-medicine/grindeks-brand-products/mildronate|title=Mildronate|website=Grindeks.lv|accessdate=2016-03-09|deadurl=yes|archiveurl=https://web.archive.org/web/20160312213702/http://www.grindeks.lv/en/products/prescription-medicine/grindeks-brand-products/mildronate|archivedate=2016-03-12}}</ref>。

==物理和化學性質==
米屈肼的化學名稱為「3-(2,2,2-trimethylhydraziniumyl)propionate」，即「3-(2,2,2-三甲基[[肼|肼]]基)丙酸酯」<ref name=PubChem>{{cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/123868|title=Mildronate|author=Pubchem|date=|work=nih.gov|accessdate=2016-03-09|language=en|archive-date=2020-08-11|archive-url=https://web.archive.org/web/20200811215731/https://pubchem.ncbi.nlm.nih.gov/compound/123868|dead-url=no}}</ref><ref>{{cite journal | author = Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuķe RJ, Molodchina TN, Kalviņs IJ, Lukevics E | title = 3-(2,2,2-Trimethylhydrazinium)propionate (THP)--a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties | journal = Biochemical Pharmacology | volume = 37 | issue = 2 | pages = 195–202 |date=January 1988 | pmid = 3342076 | doi =10.1016/0006-2952(88)90717-4  }}</ref>。其化學結構類似於{{le|γ-丁基甜菜碱|Gamma-butyrobetaine}}化合物，所分別的只是在γ-丁基甜菜碱的第四個碳[[亞甲基|亞甲基]]以[[氨基|氨基]]來替換。
γ-丁基甜菜碱是肉鹼合成的前驅<ref>{{cite journal | author = Fraenkel G, Friedman S | title = Carnitine | journal = Vitamins Hormones | volume = 15 | pages = 73–118 | year = 1957 | pmid = 13530702 | doi=10.1016/s0083-6729(08)60508-7}}</ref>。

於1970年代中期由當時為前蘇聯占領的拉脫維亞的[[拉脫維亞蘇維埃社會主義共和國科學院|拉脫維亞蘇維埃社會主義共和國科學院]]（即今日[[拉脫維亞有機合成研究所|拉脫維亞有機合成研究所]]的前身）科學家{{link-en|Ivars Kalviņš|Ivars Kalviņš}}於1970年研製。

==相關條目==
*[[心绞痛|心绞痛]]
*{{le|γ-丁基甜菜碱双加氧酶|Gamma-butyrobetaine dioxygenase}}
*[[肉碱|肉碱]]
*[[心肌梗死|心肌梗死]]

==參考資料==
{{Reflist|2}}

==延伸閱讀==
{{refbegin}}
* {{cite journal | authors = Rose, N.R.; McDonough, M.A.; King, O.N.; Kawamura, A. & Schofield, C.J. | title = Inhibition of 2-Oxoglutarate Dependent Oxygenases | journal = Chemical Society Reviews | volume = 40 | issue = 8; August | pages = 4364–4397 | year = 2011 | format = print, online review | pmid = 21390379 | doi = 10.1039/c0cs00203h | url = http://pubs.rsc.org/en/content/articlelanding/2011/cs/c0cs00203h#!divAbstract | access-date = 9 March 2011 | subscription = y | archive-date = 2020-08-04 | archive-url = https://web.archive.org/web/20200804171458/https://pubs.rsc.org/en/content/articlelanding/2011/CS/C0CS00203H#!divAbstract | dead-url = no }}
* [http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=7,223,797 Kalvinsh; Ivars (Ikshkile, LV), Birmans; Anatolijs: Meldonium salts, method of their preparation and pharmaceutical composition on their basis] {{Wayback|url=http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=7,223,797 |date=20170510071553 }}
{{refend}}

[[Category:抗心绞痛药|Category:抗心绞痛药]]
[[Category:作用于心血管系统的药物|Category:作用于心血管系统的药物]]
[[Category:肼|Category:肼]]
[[Category:缺血性心脏病|Category:缺血性心脏病]]
[[Category:两性离子|Category:两性离子]]